Clinical trial
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast…
NCT00121836 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00121836 |
|---|---|
| Title | A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer |
| Official title | An Open-label Study of Xeloda Plus Avastin at Time of Disease Progression in Treatment-naïve Women With HER2-negative Metastatic Breast Cancer |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Bevacizumab |
| Enrollment | 109 |
| Start date | Jun 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jul 21, 2005 |
| Last update posted | Apr 27, 2011 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: